◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksASND › EPS

Ascendis Pharma AS (ASND) EPS 2012–TTM

DATA UPDATED 2026-09-19

Ascendis Pharma AS annual earnings per share (EPS) for fiscal TTM was €11.20, compared with €-3.61 in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

ASND Annual EPS

EPS (annual)TTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Earnings Per Share (EPS)€11.20€-3.61€-6.53€-8.55€-10.40€-7.00€-8.28€-4.69€-3.17€-3.68€-2.58€-1.39€-0.57€0.38€0.12

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ASND Quarterly EPS

EPS (quarterly)2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Earnings Per Share (EPS)€2.83€9.91€-0.54€-1.00€-0.61€-1.58€-0.64€-1.69€-1.91

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EPS at Comparable Companies

More ASND metrics: Revenue · Gross Profit · Operating Income · Net Income · EBITDA · Free Cash Flow · Shares Outstanding

All ASND financial statements → Interactive ASND charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.